Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for PIK3CA Mutation
51 locations incl. Gilbert
Sponsor: Relay Therapeutics, Inc.
Sex: All·Age: 18+
Code: NCT06982521·Phase 3·Recruiting